In the last trading session, 1.03 million shares of the ProQR Therapeutics N.V (NASDAQ:PRQR) were traded, and its beta was 0.33. Most recently the company’s share price was $1.56, and it changed around -$0.24 or -13.33% from the last close, which brings the market valuation of the company to $164.13M. PRQR currently trades at a discount to its 52-week high of $4.62, offering almost -196.15% off that amount. The share price’s 52-week low was $1.07, which indicates that the current value has risen by an impressive 31.41% since then.
ProQR Therapeutics N.V stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended PRQR as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. ProQR Therapeutics N.V is expected to report earnings per share of -0.16 for the current quarter.
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
Instantly PRQR has showed a red trend with a performance of -13.33% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.0150 on recent trading dayincreased the stock’s daily price by 22.58%. The company’s shares are currently down -41.13% year-to-date, but still down -4.29% over the last five days. On the other hand, ProQR Therapeutics N.V (NASDAQ:PRQR) is 32.20% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $3.75, which translates to bulls needing to increase their stock price by 58.4% from its current value. Analyst projections state that PRQR is forecast to be at a low of $2 and a high of $5.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
The year-over-year growth rate is expected to be -9.76%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 4.95M in revenue for the current quarter. 7 analysts expect ProQR Therapeutics N.V to make 4.87M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 5.02M and 7.05M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -1.35%. Forecasts for the next quarter put sales growth at -30.91%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 25.70%. ProQR Therapeutics N.V earnings are expected to increase by -27.68% in 2025, but the outlook is negative -19.22% per year for the next five years.
PRQR Dividends
ProQR Therapeutics N.V’s next quarterly earnings report is expected to be released in June.
ADAGE CAPITAL PARTNERS GP, L.L.C., with 4.4394% or 3.63 million shares worth $6.02 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Delaware Group Equity Funds IV-Macquarie Healthcare Fund and Meridian Fund Inc-Meridian Small Cap Growth Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 620.0 shares worth $0.97 million, making up 0.59% of all outstanding shares. On the other hand, Meridian Fund Inc-Meridian Small Cap Growth Fund held roughly 520.25 shares worth around $0.81 million, which represents about 0.49% of the total shares outstanding.
